MonoGen, Inc.
TSX : MOG

MonoGen, Inc.

June 17, 2008 16:10 ET

MonoGen Announces Milestone in Imaging Effort

LINCOLNSHIRE, ILLINOIS--(Marketwire - June 17, 2008) - MonoGen, Inc. (TSX:MOG)(the "Corporation") today announced that it has successfully completed proof-of-principle in its imaging effort and has now confidently transitioned to the full product development phase of an advanced computer imaging system to aid in cervical cancer screening. MonoGen's imager will utilize proprietary technology in combination with the continued advances in computing power to provide next generation computer imaging technology to its customers.

"Over the past 12 months, MonoGen, with the assistance of Lathrop Engineering, a medical device and diagnostics product development firm, has conducted extensive feasibility studies and generated functional breadboards that have confirmed the viability of the technical approach of the MonoGen imager," said Matt Zelinski, MonoGen's Vice President of Research and Development. "In addition, after continuing discussions with the laboratory community, MonoGen believes most customers are looking for additional benefits and functionality from imaging. The MonoPrep imager will transition the laboratory into the digital age of virtual microscopy and information sharing while keeping the cytologists involved as the final decision makers in the overall screening process. Our goal is to enhance laboratory productivity while continuing to pursue the highest level of disease detection when used in conjunction with the MonoPrep Pap Test."

Bob Lathrop, President of Lathrop Engineering said, "We have been extremely excited to work with the MonoGen team in this endeavor. The technology is truly unique and will certainly change the way cytology screening is done in the future. We are pleased MonoGen has chosen us to partner with them on this important project."

Ted S. Geiselman, MonoGen President and CEO added, "We understand the importance of imaging to many laboratories and therefore feel it is important to share this significant milestone information with them. Our product will be clearly differentiated from the current offerings available from our competitors from both a technology and utility perspective. The feedback from customers who have helped in assessing our overall approach has been extremely positive. We look forward to sharing more information about the product details as we progress in this development effort."

About MonoGen, Inc.

MonoGen, Inc., headquartered in the Chicago area, is a medical device and diagnostics company providing high-quality and cost-effective cytological screening and diagnostic products to healthcare providers in the anatomic pathology industry.

Forward-Looking Statements

This press release contains forward-looking statements. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements. Forward-looking statements are based on our beliefs and assumptions based on information available at the time the assumptions were made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause our actual results to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to, our ability to raise additional capital, our ability to execute our business plan while maintaining at all times our various regulatory approvals, and the response from existing and potential competitors. Additional discussions of the various risks are contained in our Annual Information Form dated March 19, 2008, which is available on SEDAR (www.sedar.com). Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document.

Contact Information